(Q24202000)

6

0 references

Gerhild Becker

Gerhild Becker

7

0 references

Joerg J Meerpohl

Joerg J Meerpohl

2

0 references

Carola Xander

1

Carola Xander

0 references

Daniel Galandi

3

Daniel Galandi

0 references

author name string

Sabine Buroh

Cochrane Database of Systematic Reviews

4

0 references

publication date

9 June 2013

0 references

published in

0 references

cites work

Ondansetron therapy for uremic pruritus in hemodialysis patients.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008320.PUB2

Comparison of rifampicin with phenobarbitone for treatment of pruritus in biliary cirrhosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008320.PUB2

Gabapentin in patients with the pruritus of cholestasis: a double-blind, randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008320.PUB2

Relief of pruritus and decreases in plasma histamine concentrations during erythropoietin therapy in patients with uremia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008320.PUB2

Lack of efficacy of tacrolimus ointment 0.1% for treatment of hemodialysis-related pruritus: a randomized, double-blind, vehicle-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008320.PUB2

Gabapentin therapy for pruritus in haemodialysis patients: a randomized, placebo-controlled, double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008320.PUB2

The potent bile acid sequestrant colesevelam is not effective in cholestatic pruritus: results of a double-blind, randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008320.PUB2

Effect of a novel kappa-receptor agonist, nalfurafine hydrochloride, on severe itch in 337 haemodialysis patients: a Phase III, randomized, double-blind, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008320.PUB2

A comparative study on the effects of naltrexone and loratadine on uremic pruritus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008320.PUB2

A randomized, placebo-controlled, double-blind trial of ondansetron in renal itch

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008320.PUB2

A controlled trial of ondansetron in the pruritus of cholestasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008320.PUB2

Relief of idiopathic generalized pruritus in dialysis patients treated with activated oral charcoal

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008320.PUB2

Cholestyramine in uraemic pruritus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008320.PUB2

Pruritus in HIV-1 disease: therapy with drugs which may modulate the pattern of immune dysregulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008320.PUB2

Effect of oral cromolyn sodium on CKD-associated pruritus and serum tryptase level: a double-blind placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008320.PUB2

Efficacy of lidocaine in the treatment of pruritus in patients with chronic cholestatic liver diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008320.PUB2

Kappa-opioid system in uremic pruritus: multicenter, randomized, double-blind, placebo-controlled clinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008320.PUB2

A pramoxine-based anti-itch lotion is more effective than a control lotion for the treatment of uremic pruritus in adult hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008320.PUB2

Paroxetine in the treatment of severe non-dermatological pruritus: a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008320.PUB2

The use of pregabalin in the treatment of uraemic pruritus in haemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008320.PUB2

Effects of naloxone infusions in patients with the pruritus of cholestasis. A double-blind, randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008320.PUB2

Efficacy of pentoxifylline in the treatment of pruritic papular eruption of HIV-infected persons

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008320.PUB2

Topical capsaicin for treatment of hemodialysis-related pruritus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008320.PUB2

21 January 2018

Mirtazapine for pruritus

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008320.PUB2

Thalidomide for the control of severe paraneoplastic pruritus associated with Hodgkin's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008320.PUB2

Treatment of pruritus caused by cholestasis with opioid antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008320.PUB2

Polymethylmethacrylate efficacy in reduction of renal itching in hemodialysis patients: crossover study and role of tumor necrosis factor-alpha.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008320.PUB2

Carbamazepine can be effective in alleviating tormenting pruritus in patients with hematologic malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008320.PUB2

A prospective proof of concept study of the efficacy of tacrolimus ointment on uraemic pruritus (UP) in patients on chronic dialysis therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008320.PUB2

Topical capsaicin--a novel and effective treatment for idiopathic intractable pruritus ani: a randomised, placebo controlled, crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008320.PUB2

Effect of oral naltrexone on pruritus in cholestatic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008320.PUB2

Treatment of refractory cholestatic pruritus with molecular adsorbent recirculating system (MARS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008320.PUB2

Treatment of pruritus of primary biliary cirrhosis with rifampin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008320.PUB2

The use of midazolam to treat itching in a terminally ill patient with biliary obstruction

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008320.PUB2

Gabapentin and uremic pruritus in hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008320.PUB2

Treatment of chronic pruritus with the selective serotonin re-uptake inhibitors paroxetine and fluvoxamine: results of an open-labelled, two-arm proof-of-concept study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008320.PUB2

Zinc sulfate for relief of pruritus in patients on maintenance hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008320.PUB2

Pruritus in primary biliary cirrhosis: pathogenesis and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008320.PUB2

Itch and pruritus: what are they, and how should itches be classified?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008320.PUB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008320.PUB2

Topical capsaicin (low concentration) for chronic neuropathic pain in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008320.PUB2

Topical capsaicin (high concentration) for chronic neuropathic pain in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008320.PUB2

Topical therapies for pruritus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008320.PUB2

Systematic review of topical capsaicin in the treatment of pruritus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008320.PUB2

Quantifying heterogeneity in a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008320.PUB2

A multicenter evaluation of cancer pain control by palliative care teams.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008320.PUB2

21 January 2018

The neurobiology of itch

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008320.PUB2

The pruritus of cholestasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008320.PUB2

Pruritus associated with cholestasis. A review of pathogenesis and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008320.PUB2

Understanding pruritus in systemic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008320.PUB2

Pruritus in advanced internal diseases. Pathogenesis and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008320.PUB2

Pruritus measurement and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008320.PUB2

Uraemic pruritus: clinical characteristics, pathophysiology and treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008320.PUB2

Review article: pruritus in cholestatic and other liver diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008320.PUB2

Uraemic pruritus--new perspectives and insights from recent trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008320.PUB2

Chronic pruritus--pathogenesis, clinical aspects and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008320.PUB2

Etiology and prognostic significance of severe uremic pruritus in chronic hemodialysis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008320.PUB2

Haloperidol for the treatment of nausea and vomiting in palliative care patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008320.PUB2

Antipruritic treatment with systemic μ-opioid receptor antagonists: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008320.PUB2

Symptoms in 400 patients referred to palliative care services: prevalence and patterns.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008320.PUB2

Relief of cholestatic pruritus by a novel class of drugs: 5-hydroxytryptamine type 3 (5-HT3) receptor antagonists: effectiveness of ondansetron

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008320.PUB2

Neurophysiological, neuroimmunological, and neuroendocrine basis of pruritus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008320.PUB2

Pruritus: management algorithms and experimental therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008320.PUB2

Neurophysiological and neurochemical basis of modern pruritus treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008320.PUB2

Pharmacologic advances in the systemic treatment of itch

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008320.PUB2

The efficacy and safety of bile Acid binding agents, opioid antagonists, or rifampin in the treatment of cholestasis-associated pruritus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008320.PUB2

Neurotropic and psychotropic drugs in dermatology

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008320.PUB2

Molecular regulation of hepatobiliary transport systems: clinical implications for understanding and treating cholestasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008320.PUB2

Analyzing multiple endpoints in clinical trials of pain treatments: IMMPACT recommendations. Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008320.PUB2

The symptoms of advanced cancer: relationship to age, gender, and performance status in 1,000 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008320.PUB2

New insights into the pathophysiology and treatment of chronic itch in patients with end-stage renal disease, chronic liver disease, and lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008320.PUB2

How useful are systematic reviews for informing palliative care practice? Survey of 25 Cochrane systematic reviews

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008320.PUB2

Epidemiology of itch: adding to the burden of skin morbidity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008320.PUB2

Ondansetron. A review of its pharmacology and preliminary clinical findings in novel applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008320.PUB2

Activated charcoal rediscovered.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008320.PUB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008320.PUB2

Multicentre randomized placebo-controlled trial of ursodeoxycholic acid with or without colchicine in symptomatic primary biliary cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008320.PUB2

Sertraline as a first-line treatment for cholestatic pruritus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008320.PUB2

7 January 2021

[Antidepressant drugs : a reasonable therapy for pruritus?]

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008320.PUB2

7 January 2021

Rifampicin as treatment for pruritus in malignant cholestasis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008320.PUB2

7 January 2021

A controlled trial of naloxone infusions for the pruritus of chronic cholestasis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008320.PUB2

7 January 2021

Double-blind, placebo-controlled study of nicergoline in the treatment of pruritus in patients receiving maintenance hemodialysis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008320.PUB2

7 January 2021

Uremic pruritus: still an important clinical problem

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008320.PUB2

7 January 2021

Treatment of pruritus with topically applied opiate receptor antagonist

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008320.PUB2

7 January 2021

Cholestyramine therapy in patients with a paucity of intrahepatic bile ducts

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008320.PUB2

7 January 2021

Pharmacologic control of pruritus.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008320.PUB2

7 January 2021

A comparative trial of trimeprazine and amylobarbitone in pruritus

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008320.PUB2

7 January 2021

Randomised crossover trial of naltrexone in uraemic pruritus

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008320.PUB2

7 January 2021

Itch-associated response induced by intradermal serotonin through 5-HT2 receptors in mice

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008320.PUB2

7 January 2021

Efficacy and safety of oral naltrexone treatment for pruritus of cholestasis, a crossover, double blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008320.PUB2

7 January 2021

Generalized pruritus and systemic disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008320.PUB2

7 January 2021

Should the patient with generalized pruritus be evaluated for malignancy?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008320.PUB2

7 January 2021

Uremic pruritus: roles of parathyroid hormone and substance P

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008320.PUB2

7 January 2021

Oral nalmefene therapy reduces scratching activity due to the pruritus of cholestasis: a controlled study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008320.PUB2

7 January 2021

Oral naltrexone treatment for cholestatic pruritus: A double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008320.PUB2

7 January 2021

Therapeutic effect of topical gamma-linolenic acid on refractory uremic pruritus

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008320.PUB2

7 January 2021

Renal transplantation

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008320.PUB2

7 January 2021

Treatment of severe refractory pruritus with fractionated plasma separation and adsorption (Prometheus)

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008320.PUB2

7 January 2021

Treatment of pruritus in chronic liver disease with the 5-hydroxytryptamine receptor type 3 antagonist ondansetron: a randomized, placebo-controlled, double-blind cross-over trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008320.PUB2

7 January 2021

Flumecinol for the treatment of pruritus associated with primary biliary cirrhosis.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008320.PUB2

7 January 2021

Behavioural treatment of scratching in patients with atopic dermatitis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008320.PUB2

7 January 2021

The prevalence of skin disease in HIV infection and its relationship to the degree of immunosuppression

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008320.PUB2

7 January 2021

The immunosuppressive drug thalidomide induces T helper cell type 2 (Th2) and concomitantly inhibits Th1 cytokine production in mitogen- and antigen-stimulated human peripheral blood mononuclear cell cultures

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008320.PUB2

7 January 2021

Rifampin is safe for treatment of pruritus due to chronic cholestasis: a meta-analysis of prospective randomized-controlled trials

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008320.PUB2

7 January 2021

Ondansetron: a selective 5-HT(3) receptor antagonist and its applications in CNS-related disorders.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008320.PUB2

7 January 2021

Effective treatment of pruritus with naltrexone, an orally active opiate antagonist

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008320.PUB2

7 January 2021

Cimetidine for pruritus in Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008320.PUB2

7 January 2021

https://api.crossref.org/works/10.1002%2F14651858.CD008320.PUB2

1 reference

7 January 2021

Histamine and serotonin in uremic pruritus: effect of ondansetron in CAPD-pruritic patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008320.PUB2

7 January 2021

Uremic pruritus: an unresolved problem in hemodialysis patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008320.PUB2

7 January 2021

Electrical needle therapy of uremic pruritus

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008320.PUB2

7 January 2021

Thalidomide for the treatment of uremic pruritus: a crossover randomized double-blind trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008320.PUB2

7 January 2021

Oral activated charcoal in patients with uremic pruritus

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008320.PUB2

7 January 2021

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008320.PUB2

7 January 2021

Specific C-receptors for itch in human skin.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008320.PUB2

7 January 2021

Efficacy of topical cromolyn sodium 4% on pruritus in uremic nephrogenic patients: a randomized double-blind study in 60 patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008320.PUB2

7 January 2021